The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating misfolded protein diseases comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating selective autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

An amine of formula (I) in a curing agent for epoxy resins, a curing agent for epoxy resins containing the amine of formula (I) and resultant epoxy resin compositions which can be used particularly as low-emission room-temperature-curing epoxy resin coatings demonstrating good workability, rapid curing, a high degree of hardness and high surface quality. The amine of formula (I) is low-odour, can be handled well at room temperature even without dilution, and can be produced at high purity in a simple process.

An amine of formula (I) in a curing agent for epoxy resins, a curing agent for epoxy resins containing the amine of formula (I) and resultant epoxy resin compositions which can be used particularly as low-emission room-temperature-curing epoxy resin coatings demonstrating good workability, rapid curing, a high degree of hardness and high surface quality. The amine of formula (I) is low-odour, can be handled well at room temperature even without dilution, and can be produced at high purity in a simple process.

Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.

Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.

Compounds and methods of using the same for treating conditions alleviated by SKI complex inhibition, viral replication inhibition, or interferon signaling inducement are provided.

Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.

Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.

The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

The present invention provides compounds having store overload-induced Ca.sup.2+ release (SOICR) inhibitory activity and methods for producing and using the same. In particular, compounds of the invention is of the formula: R.sup.1X.sup.1-L-X.sup.2R.sup.2, wherein R.sup.1, X.sup.1, L, X.sup.2, and R.sup.2 are those defined herein.